Gene Transfer Techniques for the Delivery of GDNF in Parkinson's Disease

  1. Derek J. Chadwick Organizer and
  2. Jamie A. Goode
  1. Jean-Luc Ridet,
  2. Nicole Déglon and
  3. Patrick Aebischer*

Published Online: 7 OCT 2008

DOI: 10.1002/0470870834.ch13

Neural Transplantation in Neurodegenerative Disease: Current Status and New Directions: Novartis Foundation Symposium 231

Neural Transplantation in Neurodegenerative Disease: Current Status and New Directions: Novartis Foundation Symposium 231

How to Cite

Ridet, J.-L., Déglon, N. and Aebischer, P. (2000) Gene Transfer Techniques for the Delivery of GDNF in Parkinson's Disease, in Neural Transplantation in Neurodegenerative Disease: Current Status and New Directions: Novartis Foundation Symposium 231 (eds D. J. Chadwick and J. A. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470870834.ch13

Author Information

  1. Division of Surgical Research and Gene Therapy Center, Lausanne University Medical School, Centre Hospitalier Universitaire Vaudois, Pavillon 4, CH-1011 Lausanne, Switzerland

*Division of Surgical Research and Gene Therapy Center, Lausanne University Medical School, Centre Hospitalier Universitaire Vaudois, Pavillon 4, CH-1011 Lausanne, Switzerland

Publication History

  1. Published Online: 7 OCT 2008
  2. Published Print: 23 OCT 2000

Book Series:

  1. Novartis Foundation Symposia

Book Series Editors:

  1. Novartis Foundation

ISBN Information

Print ISBN: 9780471492467

Online ISBN: 9780470870839

SEARCH

Summary

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor disturbances caused by an alteration of the dopaminergic nigrostriatal system. Current symptomatic treatments for PD include dopaminergic drug administration, deep brain stimulation, ablative surgery and fetal cell transplantation. Though these approaches have significant beneficial effects, they are hampered by limiting side-effects, but more importantly they do not change the disease progression. Alternative restorative and neuroprotective strategies have therefore to be considered. Neuroprotective effects of neurotrophic factors, anti-apoptotic and antioxidant molecules are currently being investigated for this purpose. Among neurotrophic molecules, the potential of the glial cell line-derived neurotrophic factor (GDNF) to protect the nigral dopaminergic neurons and/or rescue striatal dopamine levels has been extensively documented. For GDNF to become a clinical reality, appropriate delivery techniques will have to be developed. This chapter focuses on the potential of encapsulated cells and viral vectors to locally release neurotrophic factors in experimental models of PD.